Asia-pacific Drug Discovery Market Forecast 2022-2030
Description
Asia-pacific Drug Discovery Market Forecast 2022-2030
KEY FINDINGS
The Asia-Pacific drug discovery market is predicted to register a CAGR of 7.13% during the forecast period, 2022-2030. The existing healthcare challenges and the dense population base offer lucrative research and clinical trials opportunities for pharmaceuticals and CROs.
MARKET INSIGHTS
Taiwan, Japan, Australia & New Zealand, India, Singapore, Indonesia, South Korea, China, and Rest of Asia-Pacific are analyzed for the Asia-Pacific drug discovery market growth evaluation. In Japan, product initiatives and launches contribute to market growth. For instance, the Pharmaceuticals and Medical Devices Agency is a regulatory agency that collaborates with the Ministry of Health, Labour and Welfare to protect public health by assuring the quality, efficacy, and safety of medical and pharmaceuticals. Also, the Tokyo Medical and Dental University announced a technology that uses AI (artificial intelligence) for discovering drug resistance’s new casual mechanisms in cancer treatments from clinical data.
India has a strong foothold and drug manufacturing capacities in generic drugs production and sales. Several industry experts of prominent Indian pharma companies are prioritizing novel drug discovery and development. Also, the industry leaders are modernizing, enhancing, and developing their R&D capabilities. In addition, the Drugs Controller General of India (DCGI) regulates the imports and sales of drugs for clinical trial use and permits clinical trials. Further, the government introduced the country’s first-ever national initiative for supplementing the drug discovery process in July 2020.
In Indonesia, the NA-DFC (National Agency of Drug and Food Control) ensures the efficacy, quality, and safety of pharmaceuticals in Indonesia. It grants drug approvals in the form of a marketing authorization license and oversees the drug registration application review process. Such factors drive market growth in these countries.
COMPETITIVE INSIGHTS
Some of the eminent companies in the market include AstraZeneca Plc, Charles River, Laboratories International Inc, Bayer AG, Eli Lilly and Company, etc.
Our report offerings include:
Explore key findings of the overall market
Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
Market Segmentation cater to a thorough assessment of key segments with their market estimations
Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
KEY FINDINGS
The Asia-Pacific drug discovery market is predicted to register a CAGR of 7.13% during the forecast period, 2022-2030. The existing healthcare challenges and the dense population base offer lucrative research and clinical trials opportunities for pharmaceuticals and CROs.
MARKET INSIGHTS
Taiwan, Japan, Australia & New Zealand, India, Singapore, Indonesia, South Korea, China, and Rest of Asia-Pacific are analyzed for the Asia-Pacific drug discovery market growth evaluation. In Japan, product initiatives and launches contribute to market growth. For instance, the Pharmaceuticals and Medical Devices Agency is a regulatory agency that collaborates with the Ministry of Health, Labour and Welfare to protect public health by assuring the quality, efficacy, and safety of medical and pharmaceuticals. Also, the Tokyo Medical and Dental University announced a technology that uses AI (artificial intelligence) for discovering drug resistance’s new casual mechanisms in cancer treatments from clinical data.
India has a strong foothold and drug manufacturing capacities in generic drugs production and sales. Several industry experts of prominent Indian pharma companies are prioritizing novel drug discovery and development. Also, the industry leaders are modernizing, enhancing, and developing their R&D capabilities. In addition, the Drugs Controller General of India (DCGI) regulates the imports and sales of drugs for clinical trial use and permits clinical trials. Further, the government introduced the country’s first-ever national initiative for supplementing the drug discovery process in July 2020.
In Indonesia, the NA-DFC (National Agency of Drug and Food Control) ensures the efficacy, quality, and safety of pharmaceuticals in Indonesia. It grants drug approvals in the form of a marketing authorization license and oversees the drug registration application review process. Such factors drive market growth in these countries.
COMPETITIVE INSIGHTS
Some of the eminent companies in the market include AstraZeneca Plc, Charles River, Laboratories International Inc, Bayer AG, Eli Lilly and Company, etc.
Our report offerings include:
Explore key findings of the overall market
Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
Market Segmentation cater to a thorough assessment of key segments with their market estimations
Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
Table of Contents
165 Pages
- 1. Research Scope & Methodology
- 1.1. Study Objectives
- 1.2. Scope Of Study
- 1.3. Methodology
- 1.4. Assumptions & Limitations
- 2. Executive Summary
- 2.1. Market Size & Estimates
- 2.2. Market Overview
- 3. Market Dynamics
- 3.1. Key Drivers
- 3.1.1. Growing R&D For Tackling Several Diseases
- 3.1.2. Technological Advancements
- 3.2. Key Restraints
- 3.2.1. Extensive Time-consuming Process
- 3.2.2. Highly Regulated Market
- 3.2.3. Project Feasibility And Success Rate
- 4. Key Analytics
- 4.1. Impact Of Covid-19 On Drug Discovery Market
- 4.2. Key Market Trends
- 4.3. Porter’s Five Forces Analysis
- 4.3.1. Buyers Power
- 4.3.2. Suppliers Power
- 4.3.3. Substitution
- 4.3.4. New Entrants
- 4.3.5. Industry Rivalry
- 4.4. Opportunity Matrix
- 4.5. Drug Discovery And Development Process
- 4.5.1. Drug Discovery And Development
- 4.5.2. Preclinical Research
- 4.5.3. Clinical Research
- 4.5.4. Regulatory Authority Review
- 4.5.5. Post Market Safety Monitoring
- 4.6. Regulatory Framework
- 5. Market By Drug Type
- 5.1. Small Molecule Drug
- 5.2. Biologic Drug
- 6. Market By Service
- 6.1. Chemical Services
- 6.2. Drug Metabolism And Pharmacokinetics Services
- 6.3. Biological Services
- 6.4. Other Pharmaceutical Services
- 7. Market By End-user
- 7.1. Pharmaceutical Companies
- 7.2. Contract Research Organizations
- 7.3. Research Institutes
- 7.4. Other End-users
- 8. Market By Technology
- 8.1. High Throughput Screening
- 8.2. Spectroscopy
- 8.3. Combinatorial Chemistry
- 8.4. Biochips
- 8.5. Pharmacogenomics And Pharmacogenetics
- 8.6. Bioinformatics
- 8.7. Metabolomics
- 8.8. Nanotechnology
- 8.9. Other Technologies
- 9. Geographical Analysis
- 9.1. Asia-pacific
- 9.1.1. Market Size & Estimates
- 9.1.2. Key Growth Enablers
- 9.1.3. Key Challenges
- 9.1.4. Key Players
- 9.1.5. Country Analysis
- 9.1.5.1. China
- 9.1.5.2. Japan
- 9.1.5.3. India
- 9.1.5.4. South Korea
- 9.1.5.5. Indonesia
- 9.1.5.6. Singapore
- 9.1.5.7. Taiwan
- 9.1.5.8. Australia & New Zealand
- 9.1.5.9. Rest Of Asia-pacific
- 10. Competitive Landscape
- 10.1. Key Strategic Developments
- 10.1.1. Mergers & Acquisitions
- 10.1.2. Product Launches & Developments
- 10.1.3. Partnerships & Agreements
- 10.1.4. Business Expansions & Divestitures
- 10.2. Company Profiles
- 10.2.1. Agilent Technologies Inc
- 10.2.2. Astrazeneca Plc
- 10.2.3. Bayer Ag
- 10.2.4. Charles River Laboratories International Inc
- 10.2.5. Eli Lilly And Company
- 10.2.6. Evotec Se
- 10.2.7. Glaxosmithkline Plc
- 10.2.8. Icon Plc
- 10.2.9. Iqvia Holdings Inc
- 10.2.10. Johnson & Johnson
- 10.2.11. Merck & Co Inc
- 10.2.12. Novartis Ag
- 10.2.13. Pfizer Inc
- 10.2.14. Roche Ag
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.